CN EN

news

BioDuro-Sundia CEO gave a keynote speech at the 2022 J.P. Morgan Healthcare Conference!

BioDuro-Sundia CEO presented at the 2022 J.P. Morgan Healthcare Conference, discussing their CRDMO services from drug discovery to manufacturing.
January 14, 2022

BioDuro-Sundia Receives 2021 Best Partner Award from Haihe Biopharma Drug Discovery Department

BioDuro-Sundia won the “Best Partner Award in Chemistry & Biology 2021” issued by Haihe Biopharma , in recognitionby our drug discovery team.
January 06, 2022

BioDuro-Sundia Acquires 2nd US-based Commercial Drug Product Manufacturing Facility along with Commercial Supply Agreement

BioDuro-Sundia announced today that it has signed a definitive agreement to acquire a commercial oral solid dose pharmaceutical product manufacturing facility.
November 08, 2021

Congratulations to Immunophage Biotech on the US FDA Approval to Initiate Clinical Trials for their Small Molecule MIF Inhibitor IPG1094

SHANGHAI, August 27, 2021 – Congratulations to our partner, Nanjing Immunophage Biotech, for receiving Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to in
August 27, 2021

BioDuro-Sundia Acquires US-based Phase III/Commercial Drug Product Manufacturing Facility

Bioduro-Sundia Acquires Us-Based Phase Iii/Commercial Drug Product Manufacturing Facility, Begin Commercial Service Operations At The Site On January 1, 2022.
August 23, 2021
Total 84 12345678...1617
0.171952s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all